2007
DOI: 10.1097/01.jto.0000263720.15062.51
|View full text |Cite
|
Sign up to set email alerts
|

Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline

Abstract: Evidence on the clinical benefit of second-line therapy in SCLC is limited. Topotecan is the most studied agent in this population; it has a response and survival benefit in comparison with placebo, but it also has greater toxicity in comparison with CAV. To date, significant differences in terms of response and survival are not evident in studied chemotherapy options.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
46
0

Year Published

2008
2008
2021
2021

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 78 publications
(48 citation statements)
references
References 8 publications
2
46
0
Order By: Relevance
“…S1K-O 25 . Cell line relevant IC 25 and IC 50 values that were used in these experiments were similar to flavopiridol and doxorubicin doses summarized in Fig. 2.…”
Section: Resultsmentioning
confidence: 69%
See 3 more Smart Citations
“…S1K-O 25 . Cell line relevant IC 25 and IC 50 values that were used in these experiments were similar to flavopiridol and doxorubicin doses summarized in Fig. 2.…”
Section: Resultsmentioning
confidence: 69%
“…SCLC cell lines have been observed to be highly sensitive to flavopiridol-induced apoptosis. In our study, the de novo Rb-negative cell line H69 was the most sensitive cell line to both flavopiridol (IC 50 Sequential flavopiridol and doxorubicin combination has a synergistic cytotoxic effect on Rb-negative SCLC cell lines. Flalavopiridol combinations with a variety of chemotherapeutic agents are observed to have either synergistic or antagonistic effects depending on their administration schedule (31).…”
Section: Resultsmentioning
confidence: 70%
See 2 more Smart Citations
“…The efficacy of second line chemotherapy in relapsed SCLC is largely dependent on the treatment-free interval, the extent of response and the residual toxicity from first-line therapy, as well as the performance status of the patient [22;23]. Nevertheless, even in late relapse, treatment with other agents is often less effective than the initial chemotherapy; the response rate with the approved second-line therapy, topotecan, is only about 20% [24]. For patients who fail to respond to or who relapsed shortly after the completion of first-line chemotherapy the response to most agents or regimens is poor and currently there is no standard second-line treatment [7].…”
Section: Discussionmentioning
confidence: 99%